Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (962)	11/20/1997 1:54:00 PM
From: D.Right	Respond to of 2173

Dear Henry: The Novo Nordisk's drug is a stimulater for insulin secretion, and it main target population is type II patients who do not inject insulin daily. You know AMLN's pramlintide is not targeting this type of patients in their current clinical IIIs. Don't tell me you don't know that. Yes, the two percent reduction of glycosolated hemoglobin is very good number, but I believe the control here is for those patients who don't use any medicine at all. Correct me if I am wrong. D.Right

To: Henry Niman who wrote (962)	11/20/1997 8:47:00 PM
From: arnie h	Respond to of 2173

Henry, Not clear what this has "to do with the case" to quote Gilbert & Sullivan's Mikado. My wife takes 1 pill of Glynase a day and is not insulin dependent. She's in the target population for Repaglinide but the Glynase does a marvelous job of controlling her disease. I don't know why she would be interested in this new pill and it is obviously not intended for those who require insulin injection. I sure hope Amylin isn't targeting my wife. If they are, they should stop the study now because they won't get any further than Novo Nordisk will. Arnie